Bifurcations in coupled amyloid-β aggregation-inflammation systems.
Journal
NPJ systems biology and applications
ISSN: 2056-7189
Titre abrégé: NPJ Syst Biol Appl
Pays: England
ID NLM: 101677786
Informations de publication
Date de publication:
30 Jul 2024
30 Jul 2024
Historique:
received:
27
03
2024
accepted:
23
07
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
30
7
2024
Statut:
epublish
Résumé
A complex interplay between various processes underlies the neuropathology of Alzheimer's disease (AD) and its progressive course. Several lines of evidence point to the coupling between Aβ aggregation and neuroinflammation and its role in maintaining brain homeostasis during the long prodromal phase of AD. Little is however known about how this protective mechanism fails and as a result, an irreversible and progressive transition to clinical AD occurs. Here, we introduce a minimal model of a coupled system of Aβ aggregation and inflammation, numerically simulate its dynamical behavior, and analyze its bifurcation properties. The introduced model represents the following events: generation of Aβ monomers, aggregation of Aβ monomers into oligomers and fibrils, induction of inflammation by Aβ aggregates, and clearance of various Aβ species. Crucially, the rates of Aβ generation and clearance are modulated by inflammation level following a Hill-type response function. Despite its relative simplicity, the model exhibits enormously rich dynamics ranging from overdamped kinetics to sustained oscillations. We then specify the region of inflammation- and coupling-related parameters space where a transition to oscillatory dynamics occurs and demonstrate how changes in Aβ aggregation parameters could shift this oscillatory region in parameter space. Our results reveal the propensity of coupled Aβ aggregation-inflammation systems to oscillatory dynamics and propose prolonged sustained oscillations and their consequent immune system exhaustion as a potential mechanism underlying the transition to a more progressive phase of amyloid pathology in AD. The implications of our results in regard to early diagnosis of AD and anti-AD drug development are discussed.
Identifiants
pubmed: 39080352
doi: 10.1038/s41540-024-00408-7
pii: 10.1038/s41540-024-00408-7
doi:
Substances chimiques
Amyloid beta-Peptides
0
Protein Aggregates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
80Subventions
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : RE 3655/2-3
Informations de copyright
© 2024. The Author(s).
Références
D. S. A. s. D. I. Alzheimer’s Disease International, ADI https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/ (2024).
DeTure, M. A. & Dickson, D. W. The neuropathological diagnosis of Alzheimer’s disease. Mol. Neurodegener. 14, 32 (2019).
pubmed: 31375134
pmcid: 6679484
doi: 10.1186/s13024-019-0333-5
Heneka, M. T., Kummer, M. P. & Latz, E. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 14, 463–477 (2014).
pubmed: 24962261
doi: 10.1038/nri3705
Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8, 595–608 (2016).
pubmed: 27025652
pmcid: 4888851
doi: 10.15252/emmm.201606210
Haass, C. Take five–BACE and the gamma-secretase quartet conduct Alzheimer’s amyloid beta-peptide generation. EMBO J. 23, 483–488 (2004).
pubmed: 14749724
pmcid: 1271800
doi: 10.1038/sj.emboj.7600061
Zukowska, J., Moss, S. J., Subramanian, V. & Acharya, K. R. Molecular basis of selective amyloid-beta degrading enzymes in Alzheimer’s disease. FEBS J. https://doi.org/10.1111/febs.16939 (2023).
Iliff, J. J. et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci. Transl. Med. 4, 147ra111 (2012).
pubmed: 22896675
pmcid: 3551275
doi: 10.1126/scitranslmed.3003748
Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 8, 101–112 (2007).
pubmed: 17245412
doi: 10.1038/nrm2101
Weggen, S. & Beher, D. Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer’s disease. Alzheimers Res. Ther. 4, 9 (2012).
pubmed: 22494386
pmcid: 3334542
doi: 10.1186/alzrt107
Mawuenyega, K. G. et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 330, 1774 (2010).
pubmed: 21148344
pmcid: 3073454
doi: 10.1126/science.1197623
Webers, A., Heneka, M. T. & Gleeson, P. A. The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer’s disease. Immunol. Cell Biol. 98, 28–41 (2020).
pubmed: 31654430
doi: 10.1111/imcb.12301
Hensley, K. Neuroinflammation in Alzheimer’s disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J. Alzheimers Dis. 21, 1–14 (2010).
pubmed: 20182045
pmcid: 3792565
doi: 10.3233/JAD-2010-1414
Leng, F. & Edison, P. Neuroinflammation and microglial activation in Alzheimer disease: Where do we go from here? Nat. Rev. Neurol. 17, 157–172 (2021).
pubmed: 33318676
doi: 10.1038/s41582-020-00435-y
Porcellini, E., Ianni, M., Carbone, I., Franceschi, M. & Licastro, F. Monocyte chemoattractant protein-1 promoter polymorphism and plasma levels in alzheimer’s disease. Immun. Ageing 10, 6 (2013).
pubmed: 23432970
pmcid: 3610278
doi: 10.1186/1742-4933-10-6
Wang, W. Y., Tan, M. S., Yu, J. T. & Tan, L. Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Ann. Transl. Med. 3, 136 (2015).
pubmed: 26207229
pmcid: 4486922
de Oliveira, J. et al. Inflammatory cascade in Alzheimer’s disease pathogenesis: a review of experimental findings. Cells 10, 2581 (2021).
pubmed: 34685563
pmcid: 8533897
doi: 10.3390/cells10102581
Zhao, J., O’Connor, T. & Vassar, R. The contribution of activated astrocytes to Abeta production: implications for Alzheimer’s disease pathogenesis. J. Neuroinflammation 8, 150 (2011).
pubmed: 22047170
pmcid: 3216000
doi: 10.1186/1742-2094-8-150
Lai, A. Y. & McLaurin, J. Clearance of amyloid-beta peptides by microglia and macrophages: the issue of what, when and where. Future Neurol. 7, 165–176 (2012).
pubmed: 22737039
pmcid: 3380064
doi: 10.2217/fnl.12.6
Cariddi, L. P., Mauri, M., Cosentino, M., Versino, M. & Marino, F. Alzheimer’s disease: from immune homeostasis to neuroinflammatory condition. Int. J. Mol. Sci. 23, 13008 (2022).
doi: 10.3390/ijms232113008
Shen, J. L., Tsai, M. Y., Schafer, N. P. & Wolynes, P. G. Modeling protein aggregation kinetics: the method of second stochasticization. J. Phys. Chem. B. 125, 1118–1133 (2021).
pubmed: 33476161
doi: 10.1021/acs.jpcb.0c10331
Lomakin, A., Chung, D. S., Benedek, G. B., Kirschner, D. A. & Teplow, D. B. On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. Proc. Natl. Acad. Sci. USA. 93, 1125–1129 (1996).
pubmed: 8577726
pmcid: 40042
doi: 10.1073/pnas.93.3.1125
Pallitto, M. M. & Murphy, R. M. A mathematical model of the kinetics of beta-amyloid fibril growth from the denatured state. Biophys. J. 81, 1805–1822 (2001).
pubmed: 11509390
pmcid: 1301655
doi: 10.1016/S0006-3495(01)75831-6
Morris, A. M., Watzky, M. A., Agar, J. N. & Finke, R. G. Fitting neurological protein aggregation kinetic data via a 2-step, minimal/“Ockham’s razor” model: the Finke–Watzky mechanism of nucleation followed by autocatalytic surface growth. Biochemistry 47, 2413–2427 (2008).
pubmed: 18247636
doi: 10.1021/bi701899y
Cohen, S. I. et al. Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl. Acad. Sci. USA. 110, 9758–9763 (2013).
pubmed: 23703910
pmcid: 3683769
doi: 10.1073/pnas.1218402110
Michaels, T. C. T. et al. Dynamics of oligomer populations formed during the aggregation of Alzheimer’s Abeta42 peptide. Nat. Chem. 12, 445–451 (2020).
pubmed: 32284577
doi: 10.1038/s41557-020-0452-1
Dominguez-Andres, J. & Netea, M. G. Long-term reprogramming of the innate immune system. J. Leukoc. Biol. 105, 329–338 (2019).
pubmed: 29999546
doi: 10.1002/JLB.MR0318-104R
Moghekar, A. et al. Large quantities of Abeta peptide are constitutively released during amyloid precursor protein metabolism in vivo and in vitro. J. Biol. Chem. 286, 15989–15997 (2011).
pubmed: 21454701
pmcid: 3091208
doi: 10.1074/jbc.M110.191262
Raskatov, J. A. What Is the “Relevant” Amyloid beta42 Concentration? Chembiochem 20, 1725–1726 (2019).
pubmed: 30835961
pmcid: 6711386
doi: 10.1002/cbic.201900097
Bateman, R. J. et al. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12, 856–861 (2006).
pubmed: 16799555
pmcid: 2983090
doi: 10.1038/nm1438
Schonfelder, J. et al. Protease resistance of ex vivo amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies. Amyloid 28, 243–251 (2021).
pubmed: 34338090
doi: 10.1080/13506129.2021.1960501
Bibl, M. et al. CSF amyloid-beta-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain 129, 1177–1187 (2006).
pubmed: 16600985
pmcid: 5403412
doi: 10.1093/brain/awl063
Puzzo, D. et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci. 28, 14537–14545 (2008).
pubmed: 19118188
pmcid: 2673049
doi: 10.1523/JNEUROSCI.2692-08.2008
He, Y. et al. Soluble oligomers and fibrillar species of amyloid beta-peptide differentially affect cognitive functions and hippocampal inflammatory response. Biochem. Biophys. Res. Commun. 429, 125–130 (2012).
pubmed: 23146634
doi: 10.1016/j.bbrc.2012.10.129
Sengupta, U., Nilson, A. N. & Kayed, R. The role of amyloid-beta oligomers in toxicity, propagation, and immunotherapy. EBioMedicine 6, 42–49 (2016).
pubmed: 27211547
pmcid: 4856795
doi: 10.1016/j.ebiom.2016.03.035
Kumar, S. et al. Phosphorylation of amyloid-beta peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes. J. Biol. Chem. 287, 8641–8651 (2012).
pubmed: 22267728
pmcid: 3318721
doi: 10.1074/jbc.M111.279133
Mahul-Mellier, A. L. et al. c-Abl phosphorylates alpha-synuclein and regulates its degradation: implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson’s disease. Hum. Mol. Genet. 23, 2858–2879 (2014).
pubmed: 24412932
pmcid: 4014189
doi: 10.1093/hmg/ddt674
Hatami, A., Monjazeb, S., Milton, S. & Glabe, C. G. Familial Alzheimer’s disease mutations within the amyloid precursor protein alter the aggregation and conformation of the amyloid-beta peptide. J. Biol. Chem. 292, 3172–3185 (2017).
pubmed: 28049728
pmcid: 5336154
doi: 10.1074/jbc.M116.755264
Kumar, S. et al. Extracellular phosphorylation of the amyloid beta-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer’s disease. EMBO J. 30, 2255–2265 (2011).
pubmed: 21527912
pmcid: 3117653
doi: 10.1038/emboj.2011.138
Rezaei-Ghaleh, N., Amininasab, M., Giller, K. & Becker, S. Familial Alzheimer’s disease-related mutations differentially alter stability of amyloid-beta aggregates. J. Phys. Chem. Lett. 14, 1427–1435 (2023).
pubmed: 36734539
pmcid: 9940190
doi: 10.1021/acs.jpclett.2c03729
Rezaei-Ghaleh, N., Amininasab, M., Kumar, S., Walter, J. & Zweckstetter, M. Phosphorylation modifies the molecular stability of beta-amyloid deposits. Nat. Commun. 7, 11359 (2016).
pubmed: 27072999
pmcid: 4833870
doi: 10.1038/ncomms11359
Aprile, F. A. et al. Selective targeting of primary and secondary nucleation pathways in Abeta42 aggregation using a rational antibody scanning method. Sci. Adv. 3, e1700488 (2017).
pubmed: 28691099
pmcid: 5479649
doi: 10.1126/sciadv.1700488
Ries, M. & Sastre, M. Mechanisms of abeta clearance and degradation by glial cells. Front. Aging Neurosci. 8, 160 (2016).
pubmed: 27458370
pmcid: 4932097
doi: 10.3389/fnagi.2016.00160
Shukla, A. K. & Misra, S. Evidences and therapeutic advantages of donanemab in the treatment of early Alzheimer’s disease. J. Basic Clin. Physiol. Pharmacol. 35, 25–29 (2023).
pubmed: 38053285
doi: 10.1515/jbcpp-2023-0176
Zhang, Y., Chen, H., Li, R., Sterling, K. & Song, W. Amyloid beta-based therapy for Alzheimer’s disease: challenges, successes and future. Signal Transduct. Target Ther. 8, 248 (2023).
pubmed: 37386015
pmcid: 10310781
doi: 10.1038/s41392-023-01484-7
Novak, B. & Tyson, J. J. Design principles of biochemical oscillators. Nat. Rev. Mol. Cell. Biol. 9, 981–991 (2008).
pubmed: 18971947
pmcid: 2796343
doi: 10.1038/nrm2530
Dwyer, J. M. & Mackay, I. R. Antigen-binding lymphocytes in human blood. Lancet 1, 164–167 (1970).
pubmed: 4189239
doi: 10.1016/S0140-6736(70)90406-X
Stark, J., Chan, C. & George, A. J. Oscillations in the immune system. Immunol. Rev. 216, 213–231 (2007).
pubmed: 17367345
doi: 10.1111/j.1600-065X.2007.00501.x
Deboer, R. J., Perelson, A. S. & Kevrekidis, I. G. Immune network behavior.1. From stationary states to limit-cycle oscillations. Bull. Math. Biol. 55, 745–780 (1993).
doi: 10.1016/S0092-8240(05)80188-0
Deboer, R. J., Perelson, A. S. & Kevrekidis, I. G. Immune network behavior.2. From oscillations to chaos and stationary states. Bull. Math. Biol. 55, 781–816 (1993).
doi: 10.1016/S0092-8240(05)80189-2
Hao, W. R. & Friedman, A. Mathematical model on Alzheimer’s disease. BMC Syst. Biol. 10, 108 (2016).
pubmed: 27863488
pmcid: 5116206
doi: 10.1186/s12918-016-0348-2
Chami, L. & Checler, F. BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and beta-amyloid production in Alzheimer’s disease. Mol. Neurodegener. 7, 52 (2012).
pubmed: 23039869
pmcid: 3507664
doi: 10.1186/1750-1326-7-52
Rezaei-Ghaleh, N., Bakhtiari, D. & Rashidi, A. Reverse allostasis in biological systems: minimal conditions and implications. J. Theor. Biol. 426, 134–139 (2017).
pubmed: 28554610
doi: 10.1016/j.jtbi.2017.05.025
Doumic, M., Fellner, K., Mezache, M. & Rezaei, H. A bi-monomeric, nonlinear Becker–Doring-type system to capture oscillatory aggregation kinetics in prion dynamics. J. Theor. Biol. 480, 241–261 (2019).
pubmed: 31419441
doi: 10.1016/j.jtbi.2019.08.007
D’Onofrio, A. Metamodeling tumor–immune system interaction, tumor evasion and immunotherapy. Math. Comput. Modell. 47, 614–637 (2008).
doi: 10.1016/j.mcm.2007.02.032
Coventry, B. J. et al. CRP identifies homeostatic immune oscillations in cancer patients: A potential treatment targeting tool? J. Transl. Med. 7, 102 (2009).
pubmed: 19948067
pmcid: 2791755
doi: 10.1186/1479-5876-7-102
Shen, X. N. et al. Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. Alzheimers Dement. 16, e041476 (2020).
doi: 10.1002/alz.041476
Brosseron, F. et al. Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease. Alzheimers Res. Ther. 10, 25 (2018).
pubmed: 29482610
pmcid: 5828084
doi: 10.1186/s13195-018-0353-3
Prins, S., de Kam, M. L., Teunissen, C. E. & Groeneveld, G. J. Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease. Alzheimers Res. Ther. 14, 106 (2022).
pubmed: 35922871
pmcid: 9347121
doi: 10.1186/s13195-022-01051-2
Zimmer, E. R. et al. Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging. J. Neuroinflammation 11, 120 (2014).
pubmed: 25005532
pmcid: 4099095
doi: 10.1186/1742-2094-11-120
Passamonti, L. et al. Neuroinflammation and functional connectivity in Alzheimer’s disease: interactive influences on cognitive performance. J. Neurosci. 39, 7218–7226 (2019).
pubmed: 31320450
pmcid: 6733539
doi: 10.1523/JNEUROSCI.2574-18.2019
Chaney, A., Williams, S. R. & Boutin, H. In vivo molecular imaging of neuroinflammation in Alzheimer’s disease. J. Neurochem. 149, 438–451 (2019).
pubmed: 30339715
doi: 10.1111/jnc.14615
Masdeu, J. C., Pascual, B. & Fujita, M. Imaging neuroinflammation in neurodegenerative disorders. J. Nucl. Med. 63, 45S–52S (2022).
pubmed: 35649654
doi: 10.2967/jnumed.121.263200
Meyer-Luehmann, M. et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease. Nature 451, 720–724 (2008).
pubmed: 18256671
pmcid: 3264491
doi: 10.1038/nature06616
Hoyt, K. R. & Obrietan, K. Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics. Mol. Neurodegener. 17, 35 (2022).
pubmed: 35525980
pmcid: 9078023
doi: 10.1186/s13024-022-00537-9
Goktas, U. & Kapadia, D. Methods in Mathematica for solving ordinary differential equations. Math. Comput. Appl. 16, 784–796 (2011).
Wolfram Research, Inc. Mathematica, Version 13.3 Champaign, IL (2023).
Hoops, S. et al. COPASI: a COmplex pathway simulator. Bioinformatics 22, 3067–3074 (2006).
pubmed: 17032683
doi: 10.1093/bioinformatics/btl485